ID   SW1222
AC   CVCL_3886
SY   SW-1222; SW 1222
DR   BTO; BTO:0003105
DR   ColonAtlas; SW1222
DR   Cosmic; 876714
DR   Cosmic; 948833
DR   Cosmic; 985653
DR   Cosmic; 986017
DR   Cosmic; 995398
DR   Cosmic; 1043827
DR   Cosmic; 1223148
DR   Cosmic; 1312313
DR   Cosmic; 1479605
DR   Cosmic; 1482523
DR   Cosmic; 1524330
DR   Cosmic; 1803950
DR   Cosmic; 2302013
DR   Cosmic; 2760073
DR   Cosmic; 2800578
DR   ECACC; 12022910
DR   GEO; GSM1346888
DR   GEO; GSM1374918
DR   GEO; GSM1448088
DR   IARC_TP53; 21761
DR   Wikidata; Q54971074
DR   Ximbio; 152434
RX   PubMed=286328;
RX   PubMed=924690;
RX   PubMed=1778766;
RX   PubMed=3518877;
RX   PubMed=6220172;
RX   PubMed=6582512;
RX   PubMed=8464898;
RX   PubMed=9294210;
RX   PubMed=10737795;
RX   PubMed=16418264;
RX   PubMed=20570890;
RX   PubMed=20606684;
RX   PubMed=24755471;
RX   PubMed=25926053;
CC   From: Scott and White Clinic; Temple; USA.
CC   HLA typing: A*01 (PubMed=8464898).
CC   Microsatellite instability: Stable (MSS) (PubMed=25926053).
CC   Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu1306Ter (c.3916G>T) (E1288*, c.3862G>T); ClinVar=VCV000376059; Zygosity=Unspecified (PubMed=24755471).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Ala146Val (c.437C>T); ClinVar=VCV000375962; Zygosity=Unspecified (PubMed=20570890).
CC   Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Leu540Arg (c.1619T>G); Zygosity=Unspecified (PubMed=24755471).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Unexplicit; Ex1 113 bp del; Zygosity=Unspecified (PubMed=16418264).
CC   Omics: Deep RNAseq analysis.
CC   Omics: Transcriptome analysis.
CC   Derived from sampling site: Colon.
ST   Source(s): ECACC; PubMed=25926053
ST   Amelogenin: X,Y
ST   CSF1PO: 11
ST   D13S317: 9 (PubMed=25926053)
ST   D13S317: 9,13 (ECACC)
ST   D16S539: 9,10
ST   D21S11: 29
ST   D5S818: 9
ST   D7S820: 10,12
ST   TH01: 7
ST   TPOX: 10
ST   vWA: 18
DI   NCIt; C4349; Colon adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 23-09-21; Version: 26
//
RX   PubMed=286328; DOI=10.1073/pnas.76.3.1438;
RA   Herlyn M., Steplewski Z., Herlyn D., Koprowski H.;
RT   "Colorectal carcinoma-specific antigen: detection by means of
RT   monoclonal antibodies.";
RL   Proc. Natl. Acad. Sci. U.S.A. 76:1438-1442(1979).
//
RX   PubMed=924690; DOI=10.1002/ijc.2910200505;
RA   Kerbel R.S., Pross H.F., Leibovitz A.;
RT   "Analysis of established human carcinoma cell lines for
RT   lymphoreticular-associated membrane receptors.";
RL   Int. J. Cancer 20:673-679(1977).
//
RX   PubMed=1778766; DOI=10.1111/j.1349-7006.1991.tb01816.x;
RA   Takeshima E., Hamaguchi M., Watanabe T., Akiyama S., Kataoka M.,
RA   Ohnishi Y., Xiao H.Y., Nagai Y., Takagi H.;
RT   "Aberrant elevation of tyrosine-specific phosphorylation in human
RT   gastric cancer cells.";
RL   Jpn. J. Cancer Res. 82:1428-1435(1991).
//
RX   PubMed=3518877; DOI=10.3109/07357908609038260;
RA   Fogh J.;
RT   "Human tumor lines for cancer research.";
RL   Cancer Invest. 4:157-184(1986).
//
RX   PubMed=6220172;
RA   Dracopoli N.C., Fogh J.;
RT   "Polymorphic enzyme analysis of cultured human tumor cell lines.";
RL   J. Natl. Cancer Inst. 70:469-476(1983).
//
RX   PubMed=6582512; DOI=10.1073/pnas.81.2.568;
RA   Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.;
RT   "Cell surface antigens of human ovarian and endometrial carcinoma
RT   defined by mouse monoclonal antibodies.";
RL   Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984).
//
RX   PubMed=8464898; DOI=10.1073/pnas.90.7.2842;
RA   Browning M.J., Krausa P., Rowan A.J., Bicknell D.C., Bodmer J.G.,
RA   Bodmer W.F.;
RT   "Tissue typing the HLA-A locus from genomic DNA by sequence-specific
RT   PCR: comparison of HLA genotype and surface expression on colorectal
RT   tumor cell lines.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:2842-2845(1993).
//
RX   PubMed=9294210; DOI=10.1073/pnas.94.19.10330;
RA   Ilyas M., Tomlinson I.P.M., Rowan A., Pignatelli M., Bodmer W.F.;
RT   "Beta-catenin mutations in cell lines established from human
RT   colorectal cancers.";
RL   Proc. Natl. Acad. Sci. U.S.A. 94:10330-10334(1997).
//
RX   PubMed=10737795; DOI=10.1073/pnas.97.7.3352;
RA   Rowan A.J., Lamlum H., Ilyas M., Wheeler J., Straub J.,
RA   Papadopoulou A., Bicknell D.C., Bodmer W.F., Tomlinson I.P.M.;
RT   "APC mutations in sporadic colorectal tumors: a mutational 'hotspot'
RT   and interdependence of the 'two hits'.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:3352-3357(2000).
//
RX   PubMed=16418264; DOI=10.1073/pnas.0510146103;
RA   Liu Y., Bodmer W.F.;
RT   "Analysis of P53 mutations and their expression in 56 colorectal
RT   cancer cell lines.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:976-981(2006).
//
RX   PubMed=20570890; DOI=10.1158/0008-5472.CAN-10-0192;
RA   Janakiraman M., Vakiani E., Zeng Z.-S., Pratilas C.A., Taylor B.S.,
RA   Chitale D., Halilovic E., Wilson M., Huberman K., Ricarte Filho J.C.,
RA   Persaud Y., Levine D.A., Fagin J.A., Jhanwar S.C., Mariadason J.M.,
RA   Lash A., Ladanyi M., Saltz L.B., Heguy A., Paty P.B., Solit D.B.;
RT   "Genomic and biological characterization of exon 4 KRAS mutations in
RT   human cancer.";
RL   Cancer Res. 70:5901-5911(2010).
//
RX   PubMed=20606684; DOI=10.1038/sj.bjc.6605780;
RA   Bracht K., Nicholls A.M., Liu Y., Bodmer W.F.;
RT   "5-fluorouracil response in a large panel of colorectal cancer cell
RT   lines is associated with mismatch repair deficiency.";
RL   Br. J. Cancer 103:340-346(2010).
//
RX   PubMed=24755471; DOI=10.1158/0008-5472.CAN-14-0013;
RA   Mouradov D., Sloggett C., Jorissen R.N., Love C.G., Li S.,
RA   Burgess A.W., Arango D., Strausberg R.L., Buchanan D., Wormald S.,
RA   O'Connor L., Wilding J.L., Bicknell D.C., Tomlinson I.P.M., Bodmer W.F.,
RA   Mariadason J.M., Sieber O.M.;
RT   "Colorectal cancer cell lines are representative models of the main
RT   molecular subtypes of primary cancer.";
RL   Cancer Res. 74:3238-3247(2014).
//
RX   PubMed=25926053; DOI=10.1038/ncomms8002;
RA   Medico E., Russo M., Picco G., Cancelliere C., Valtorta E., Corti G.,
RA   Buscarino M., Isella C., Lamba S., Martinoglio B., Veronese S.,
RA   Siena S., Sartore-Bianchi A., Beccuti M., Mottolese M.,
RA   Linnebacher M., Cordero F., Di Nicolantonio F., Bardelli A.;
RT   "The molecular landscape of colorectal cancer cell lines unveils
RT   clinically actionable kinase targets.";
RL   Nat. Commun. 6:7002.1-7002.10(2015).
//